BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maus MV, June CH. Zoom Zoom: racing CARs for multiple myeloma. Clin Cancer Res 2013;19:1917-9. [PMID: 23444214 DOI: 10.1158/1078-0432.CCR-13-0168] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Burdach S, Kolb HJ. The vigor of defense against non-self: potential superiority of allorestricted T cells in immunotherapy of cancer? Front Oncol 2013;3:100. [PMID: 23653891 DOI: 10.3389/fonc.2013.00100] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
2 Bianchi G, Richardson PG, Anderson KC. Promising therapies in multiple myeloma. Blood 2015;126:300-10. [PMID: 26031917 DOI: 10.1182/blood-2015-03-575365] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 8.9] [Reference Citation Analysis]
3 Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 2013;31:999-1008. [PMID: 24142051 DOI: 10.1038/nbt.2725] [Cited by in Crossref: 130] [Cited by in F6Publishing: 121] [Article Influence: 14.4] [Reference Citation Analysis]
4 Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo VFI, Chu Y, Berneman ZN, Luo F, Van Acker HH, Anguille S. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. Front Immunol 2019;10:1613. [PMID: 31379824 DOI: 10.3389/fimmu.2019.01613] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 13.0] [Reference Citation Analysis]
5 Danhof S, Hudecek M, Smith EL. CARs and other T cell therapies for MM: The clinical experience. Best Pract Res Clin Haematol 2018;31:147-57. [PMID: 29909915 DOI: 10.1016/j.beha.2018.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
6 Nijhof IS, van de Donk NWCJ, Zweegman S, Lokhorst HM. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. Drugs 2018;78:19-37. [PMID: 29188449 DOI: 10.1007/s40265-017-0841-y] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 14.8] [Reference Citation Analysis]
7 Berahovich R, Zhou H, Xu S, Wei Y, Guan J, Guan J, Harto H, Fu S, Yang K, Zhu S, Li L, Wu L, Golubovskaya V. CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth. Cancers (Basel) 2018;10:E323. [PMID: 30208593 DOI: 10.3390/cancers10090323] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
8 Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 2020;34:985-1005. [PMID: 32055000 DOI: 10.1038/s41375-020-0734-z] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 36.0] [Reference Citation Analysis]
9 Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG 3rd, Liu B. The development of potential antibody-based therapies for myeloma. Blood Rev 2015;29:81-91. [PMID: 25294123 DOI: 10.1016/j.blre.2014.09.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
10 Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, Hoang B, Tunstead J, Christie AL, Kung AL, Richardson P, Munshi NC, Anderson KC. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 2014;123:3128-38. [PMID: 24569262 DOI: 10.1182/blood-2013-10-535088] [Cited by in Crossref: 227] [Cited by in F6Publishing: 216] [Article Influence: 28.4] [Reference Citation Analysis]
11 Garfall AL, Stadtmauer EA. Cellular and vaccine immunotherapy for multiple myeloma. Hematology Am Soc Hematol Educ Program 2016;2016:521-7. [PMID: 27913524 DOI: 10.1182/asheducation-2016.1.521] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
12 Golubovskaya V, Zhou H, Li F, Berahovich R, Sun J, Valentine M, Xu S, Harto H, Sienkiewicz J, Huang Y, Wu L. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma. Biomedicines 2021;9:1422. [PMID: 34680541 DOI: 10.3390/biomedicines9101422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Grywalska E, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, Niedźwiedzka-Rystwej P, Roliński J. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy. Cells 2020;9:E983. [PMID: 32316105 DOI: 10.3390/cells9040983] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
14 Guang MHZ, McCann A, Bianchi G, Zhang L, Dowling P, Bazou D, O'Gorman P, Anderson KC. Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. Leuk Lymphoma 2018;59:542-61. [PMID: 28610537 DOI: 10.1080/10428194.2017.1337115] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
15 Malek E, de Lima M, Letterio JJ, Kim BG, Finke JH, Driscoll JJ, Giralt SA. Myeloid-derived suppressor cells: The green light for myeloma immune escape. Blood Rev 2016;30:341-8. [PMID: 27132116 DOI: 10.1016/j.blre.2016.04.002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 10.5] [Reference Citation Analysis]
16 Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu J. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2014;28:917-27. [PMID: 24067492 DOI: 10.1038/leu.2013.279] [Cited by in Crossref: 238] [Cited by in F6Publishing: 239] [Article Influence: 26.4] [Reference Citation Analysis]
17 Cho SF, Anderson KC, Tai YT. BCMA CAR T-cell therapy arrives for multiple myeloma: a reality. Ann Transl Med 2018;6:S93. [PMID: 30740414 DOI: 10.21037/atm.2018.11.14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
18 Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy 2015;7:1187-99. [PMID: 26370838 DOI: 10.2217/imt.15.77] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 12.0] [Reference Citation Analysis]